Valneva SE (VALN)
| Market Cap | 856.46M |
| Revenue (ttm) | 211.09M |
| Net Income (ttm) | -119.86M |
| Shares Out | 181.05M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 98,123 |
| Open | 8.72 |
| Previous Close | 8.74 |
| Day's Range | 8.57 - 9.62 |
| 52-Week Range | 3.62 - 12.25 |
| Beta | 1.28 |
| Analysts | Strong Buy |
| Price Target | 15.75 (+65.09%) |
| Earnings Date | Nov 20, 2025 |
About VALN
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for VALN stock is "Strong Buy." The 12-month stock price target is $15.75, which is an increase of 65.09% from the latest price.
News
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.
Valneva to Further Consolidate its Operations in France
Saint- Herblain (France), November 26 , 202 5 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France as part ...
Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study
Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease...
Valneva SE (VALN) Q3 2025 Earnings Call Transcript
Valneva SE ( VALN) Q3 2025 Earnings Call November 20, 2025 9:00 AM EST Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - President, CEO & Director Peter Buh...
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
Saint-Herblain (France), November 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of the...
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Immune response successfully improved with second generation vaccine candidate Saint-Herblain (France), November 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, ...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Saint- Herblain (France), October 27 , 202 5 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1...
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
Saint-Herblain (France), October 6, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million ...
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccinatio...
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
Saint-Herblain (France), September 3 rd , 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced positive immunogenicity and safety data from the ongoing Phase 2 study of Lyme disease vaccine...
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday.
Johnson Fistel Investigates Valneva Following FDA Suspension
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Valneva SE (NASDAQ: VALN) regarding possible violations ...
Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US
Valneva SE VALN stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) suspended the license for Ixchiq, citing four new reports of serious adverse events (SAEs) consistent...
FDA suspends Valneva's chikungunya vaccine license in the U.S.
The United States Food and Drug Administration (FDA) has suspended the license for Valneva's chikungunya vaccine Ixchiq with immediate effect, the French drugmaker said on Monday.
Valneva Announces FDA's Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has su...
Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older
Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its s...
Valneva SE (VALN) Q2 2025 Earnings Call Transcript
Valneva SE (NASDAQ:VALN) Q2 2025 Earnings Conference Call August 12, 2025 9:00 AM ET Company Participants Joshua Drumm - Vice President of Investor Relations Peter Buhler - Chief Financial Officer Th...
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
Saint-Herblain (France), August 12, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its condensed consolidated financial results for the first half o...
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information
Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCH...
AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate
SEATTLE & HEIDELBERG, Germany--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE (...
Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
Saint Herblain (France), July, 11 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) will lift the temporary r...
Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults
The European Union's health regulator has lifted the temporary restriction on the use of French drugmaker Valneva's chikungunya vaccine, Ixchiq, in adults aged 65 and above, following a safety review.
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world's larges...
Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance
Saint-Herblain (France), June 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors wer...